Skip to main content
. 2020 Jul 2;11:888. doi: 10.3389/fphar.2020.00888

Table 1.

Demographics of patients by cohort (N=188). Data expressed as median (range).

Cohort A
Conventional dosing
(N = 53)
Cohort B
Model-Based Excel tool
(N = 76)
Cohort C
Model-Based Bayesian tool (N = 59)
Malignant Disease Non-malignant Disease Malignant Disease Non-malignant Disease Malignant Disease Non-malignant Disease
Number of subjects (n) 25 28 40 36 42 17
Weight (kg) 33 (7–101) 18 (3–61) 24 (8–98) 10.1 (4.9–62) 17.8 (8.1–150) 10.2 (5.8–79)
Age (years) 8.8 (0.21–29) 4.9 (0.1–21) 6.2 (0.9–24) 1.2 (0.24–19) 5.9 (0.9–20) 1.4 (0.2–17)
Gender (M/F) 14/11 17/11 28/12 19/17 28/14 13/4
Malignant disease
Acute myelogenous leukemia 16 17 11
Chronic myelogenous leukemia 3 3 1
Juvenile myelomonocytic leukemia 3 3 4
Myelodysplastic syndrome 3 0 2
Acute lymphoblastic leukemia 0 9 10
Neuroblastoma 0 8 10
Other 4
Non-malignant disease
Primary immune deficiencies 13 23 9
Inborn errors of metabolism 4 7 3
Hemoglobinopathies 8 6 3
Congenital neutropenia 3 0 2
Predefined cAUC target (mg*h/L) 86 (58–86) 58 (58–86) 82 (62–90) 62 (29–82) 83 (60–90) 60 (17–85)
Observed cAUC target (mg*h/L) 80 (43–110) 72 (53–108) 78 (54–170) 63 (24–102) 83 (59–94) 61 (15–85)

M, male; F, female.